Oncothyreon Inc (USA)  

(Public, NASDAQ:ONTY)   Watch this stock  
Find more results for Diana Jackson�
2.09
-0.06 (-2.79%)
Sep 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.07 - 2.15
52 week 1.67 - 4.08
Open 2.13
Vol / Avg. 1.24M/763,831.00
Mkt cap 152.24M
P/E     -
Div/yield     -
EPS -0.44
Shares 70.81M
Beta 1.05
Inst. own 61%
Sep 9, 2014
Oncothyreon Inc at Rodman & Renshaw Global Investment Conference
Aug 13, 2014
Oncothyreon Inc at Wedbush Securities Life Sciences Conference
Aug 11, 2014
Q2 2014 Oncothyreon Inc Earnings Call
Aug 11, 2014
Q2 2014 Oncothyreon Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -36.31% -46.37%
Return on average equity -40.34% -50.38%
Employees 43 -
CDP Score - -

Address

Suite 500, 2601 Fourth Avenue
SEATTLE, WA 98121
United States - Map
+1-206-8012100 (Phone)
+1-206-8012101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Oncothyreon Inc. (Oncothyreon), is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company�s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Its lead product candidate, Stimuvax, is a cancer vaccine being evaluated in two Phase III clinical trials for the treatment of non-small cell lung cancer (NSCLC). It has granted worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. Merck KGaA has completed enrollment of 1514 patients in the Phase III START trial of Stimuvax in NSCLC. In August 2014, Oncothyreon Inc acquired Alpine Biosciences, Inc.

Officers and directors

Robert L. Kirkman M.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Julia Marie Eastland Chief Financial Officer, Vice President - Corporate Development, Secretary
Age: 49
Bio & Compensation  - Reuters
Gary Christianson Chief Operating Officer
Age: 59
Bio & Compensation  - Reuters
Scott Peterson Ph.D. Chief Scientific Officer, Vice President - Research & Development
Age: 52
Bio & Compensation  - Reuters
Diana Hausman M.D. Chief Medical Officer, Vice President - Clinical Development
Age: 50
Bio & Compensation  - Reuters
Christopher S. Henney Ph.D. Non-Executive Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Ted W. Love M.D. Director
Age: 55
Bio & Compensation  - Reuters
Richard L. Jackson Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Daniel K. Spiegelman Independent Director
Age: 55
Bio & Compensation  - Reuters
W Vickery Stoughton Independent Director
Age: 68
Bio & Compensation  - Reuters